← Back to Screener
Propanc Biopharma, Inc. Common Stock (PPCB)
Price$1.45
Growth ScoreF
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-101.43%
Price vs S&P 500 (4W)-34.38%
VGM Score5.69
Market Capitalization$3.30M
All Metrics
Book Value / Share (Quarterly)$0.32
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.13
Price vs S&P 500 (YTD)-97.34%
EPS (TTM)$-25.66
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-25.66
EPS (Annual)$-371.22
ROI (Annual)-378.35%
Cash / Share (Quarterly)$0.01
ROA (Last FY)-300.14%
EBITD / Share (TTM)$-23.80
Cash Flow / Share (Annual)$-0.87
P/B Ratio0.31x
P/B Ratio (Quarterly)0.20x
Net Income / Employee (Annual)$-58,923,300
Net Interest Coverage (TTM)-75.11x
ROA (TTM)-88.19%
EPS Incl Extra (Annual)$-371.22
Current Ratio (Annual)1.50x
Quick Ratio (Quarterly)0.14x
3-Month Avg Trading Volume0.13M
52-Week Price Return-98.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.20
52-Week High$270.25
EPS Excl Extra (Annual)$-371.22
26-Week Price Return-93.51%
Quick Ratio (Annual)0.00x
13-Week Price Return-65.56%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)2.37x
Enterprise Value$3.38M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.03
3-Month Return Std Dev117.77%
Net Income / Employee (TTM)$-15,269,500
ROE (Last FY)-423.72%
Net Interest Coverage (Annual)-18.66x
EPS Basic Excl Extra (Annual)$-371.22
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-25.66
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.52
Free OCF CAGR (5Y)-36.13%
Price vs S&P 500 (52W)-98.56%
Year-to-Date Return-89.19%
5-Day Price Return-19.89%
EPS Normalized (Annual)$-371.22
ROA (5Y Avg)-5189.30%
Month-to-Date Return-20.33%
Cash Flow / Share (TTM)$-0.55
EBITD / Share (Annual)$-366.34
LT Debt / Equity (Annual)0.01x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-25.66
P/B Ratio (Annual)3.47x
Book Value / Share (Annual)$29.94
Price vs S&P 500 (13W)-73.81%
Beta3.22x
Revenue / Share (TTM)$0.00
ROE (TTM)-1743.60%
52-Week Low$1.45
gGradeF
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PPCBPropanc Biopharma, Inc. Common Stock | — | F | F | $1.45 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Propanc Biopharma is a development-stage biopharmaceutical company focused on oncology treatments for pancreatic, ovarian, and colorectal cancers. The company's lead candidate, PRP, is a composite formulation designed to prevent tumor recurrence and metastasis through a novel proenzyme-based approach. The product combines multiple anti-cancer mechanisms intended to improve treatment outcomes in difficult-to-treat solid tumors.